


AG Magen/Ösophagus

AIO-Studien


Abgeschlossen
Laufend und in
Planung









Sylvie Lorenzen
Klinikum rechts der Isar – München


Peter Thuss-Patience
Charité – Universitätsmedizin Berlin











Ösophagus Plattenepithel-Ca




Name	Indikation	Therapie	Anzahl Pat (in/geplant)	Endpunkt	LKP
POWER 	1st-line		n=155/300	Kein Zusatznutzen	M. Möhler et al, ASCO 2017
RAMOS 	2nd line		n=7/186	OS nach 6 Monaten	S. Lorenzen, München
RAMONA 	2nd line ≥ 65 (alle nach RCT+-OP)		n=58/75	OS nach 12 Monaten	Ebert, Mannheim









Adenokarzinome Magen und GEJ - periopereativ




	Indikation	Therapie	Anzahl Pat (in/geplant)	Endpunkt	LKP
PETRARCA (FLOT6) 	HER2 +	 FLOT FLOT + Tmab + Pmab	Phase II n=81/80	Phase II: pCR	R. Hofheinz, Mannheim
RAMSES (FLOT7) 	HER2 – PD-L1 –	 FLOT FLOT + Ram	Phase II n=180/180 Phase III n=-/758	Phase II: pCR Phase III: OS	S.E. Al-Batran, Frankfurt
DANTE (FLOT8) 	PD-L1 +/-	 FLOT FLOT + Atezo	Phase II n=215/295	DFS	S.E. Al-Batran, Frankfurt
RACE 	AEG I-III	 FLOT → RCT → OP → FLOT FLOT → OP → FLOT	Phase III n=340	DFS 3 J	R. Hofheinz, Mannheim S.Lorenzen, München
PREVENT (FLOT9) 	Diffuse	 FLOT → OP → FLOT FLOT → OP → HIPEC-FLOT	Phase III N=200	PFS	T. Götze, S. Al-Batran P. Piso






Adenokarzinome Magen und GEJ – 1st-line






Name	Indikation	Therapie	Anzahl Pat (in/geplant)	Endpunkt	LKP
Renaissance (FLOT5) 	oligometst	 FLOT → FLOT FLOT → OP → FLOT	Phase III n=126/271	OS	S.E. Al-Batran Frankfurt S. Mönig, Genf
MATEO 	1st-line HER2 -	CTX  Erhaltung S1 Fortsetzg CTX	Phase III n=165/297	OS	M. Haag, Heidelberg
Moonlight 	1st-line HER2 – PD-L1 +/-	 mFOLFOX +Nivo+Ipi mFOLFOX	Phase II n=120/118 Ab Mai Erweiterung	PFS	S.E. Al-Batran, Frankfurt, S. Lorenzen, München
INTEGA 	1st-line HER 2 + PD-L1 +/-	 mFOLFOX+Tmab+Nivo Tmab +Nivo+ Ipi	Phase II n=94/97	OS-Rate 12 Mo	A. Stein, E. Gökkurt, Hamburg

Adenokarzinome Magen und GEJ – 2 +3.-line




Name	Indikation	Therapie	Anzahl Pat (in/geplant)	Endpunkt	LKP
RAMIRIS Phase II 	2nd-line	 FOLFIRI + RAM Pacli+ Ram	Phase II n=111/111	OS Rate 6 Mo	S. Lorenzen, München P. Thuss-Patience, Berlin
RAMIRIS Phase III 	2nd-line Taxan vorbehandelt	 FOLFIRI + RAM Pacli+ Ram	Phase III n=12/318	OS	S. Lorenzen, München S.E. Al-Batran, Frankfurt
RAP 	2nd-line PD-L1 +/-	Ram+Avelumab+Pacli	Phase II n=30/59	OS Rate 6 Mo	P. Thuss-Patience, Berlin A. Stein, Hamburg

3rd line

Re- ExPEL 	3rd- line after Ram – pretreatment	TAS + Ramucirumab	Phase II	tolerability	T. Götze Frankfurt, S.E. Al- Batran Frankfurt
INTEGRATE IIB 	3rd- line	 REGONIVO best treatment leftover	Phase II/III	OS	M. Moehler, Mainz + Australien/ Japan

Perioperative Studien zur zielgerichteten Therapie bei gastroösophagealen Tumoren



AIO Studien bei gastroösophagealen Tumoren: metastasierte Erkrankung

